Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis
- 113 Downloads
After surgical resection, an ample prognosis variability among stages is observed. Multiple prognostic factors are individually studied and some CRC classifiers have been proposed. Not one have been implemented into clinical practice.
We classified 105 patients with resected CRC (stage I–III) into five molecular subtypes using BRAFV600E and RAS (KRAS; NRAS) status, and the expression of DNA mismatch repair (MMR) proteins (MLH1 and MSH2). Clinicopathological features and DFS) of distincts groups were evaluated.
Results and conclusions
RAS and BRAFV600E mutations were detected in 43.8 and 11.4% of patients, respectively. 19% of tumours had lack of expression of any MMR proteins reflecting a system deficiency (dMMR). Patients with any RAS mutation had lower DFS that patients with RAS wild type (wt) (40.23 vs 45.26 months; p value = 0.035). Of a total of five molecular subtypes, three were MMR proficient (pMMR): RAS mutated (39%), BRAFV600E mutated (6.7%) and RAS/BRAFV600E wt (35.2%); and two were dMMR: BRAFV600E mutated (4.8%) and BRAFV600E wt (14.3%). Left side tumours were more frequently observed in pMMR/RAS and BRAFV600E wt subtype, and right side tumours in dMMR subtypes. Among the three pMMR subtypes, a benefit survival was observed for patients without any mutation in BRAFv600E or RAS oncogenes (median of DFS = 45.5 vs 40.98 months in RAS mutated group; p = 0.084 and vs 34.13 in BRAFv600E mutated group; p = 0.031). Molecular classification using these biomarkers can be useful to identify groups with differences in prognosis.
KeywordsColorectal cancer Prognostic factor Molecular subtypes
Compliance with ethical standards
Conflict of interest
All authors declare that they have no competing interest.
Research involving human participants and/or animals/ethical approval
All procedures performed in studies involving human participants were in accordance with the Clinical Research Ethics Committee of General University Hospital of Valencia and by The Research Committee of Hospital of Sagunto, in accordance with the Declaration of Helsinki (1964), the Good Clinical Practices and local ethical and legal requirements (Spanish laws). This study complied with all applicable regulations for human participant studies. All authors reviewed and approved the final manuscript.
Prior to study entry, all patients provided written informed consent according to the local ethics committee regulations.
- 1.Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase. No. 11 [Internet], vol. 11. Lyon: International Agency for Research on Cancer. 2013. p. http://globocan.iarc.fr.
- 2.Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med. 2009;362(13):1246 (author reply 1246–1247).Google Scholar
- 4.Rodríguez-Moranta F, Castells A, Andreu M, Piñol V, Castellvi-Bel S, Alenda C, et al. Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations. Am J Gastroenterol. 2006;101(5):1104–11.CrossRefPubMedGoogle Scholar
- 9.Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67(6):2643–8.CrossRefPubMedGoogle Scholar
- 14.Edge T. AJCC Cancer Staging Handbook. From the AJCC cancer staging manual. 7th ed. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL TA, editor. New York: Springer; 2010.Google Scholar
- 20.Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, et al. Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC):results from NCCTG Intergroup phase III Trial N0147. J Clin Oncol. 2010;28(18s).CrossRefGoogle Scholar
- 23.Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20:5322–30.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Van Cutsem E, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011–9.CrossRefPubMedGoogle Scholar
- 25.Chen KH, Lin YL, Liau JY, Tsai JH, Tseng LH, Lin LI, et al. BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer. Med Oncol. 2016;33(5).Google Scholar
- 31.Stintzing S, Wirapati P, Lenz H-J, Neureiter D, von Weikersthal LF, Decker T. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. J Clin Oncol. 2017; 35(15)_suppl:3510.CrossRefGoogle Scholar